The German company Bayer has announced a reduction of its workforce of 10% in the world

Bayer AG plans to cut some 4,500 jobs in Germany, in line with the already announced plan to downsize its workforce in order to restructure its business following the acquisition of Monsanto, said people familiar with the company's plans.

The German company will cut about 12,000 jobs worldwide, or about 10% of its workforce, in order to increase its profitability after the Monsanto acquisition for $ 63,000 million.

In this way, cuts in their national market, where labor protections are broad, will affect the political sphere and could be costly.

The Director General, Werner BaumannIt is under pressure to show that the agreement will boost long-term growth despite a wave of claims in the United States for glyphosate, the main component of Monsanto's Roundup herbicide. A spokesman for Bayer declined to comment on the job cuts.

Bayer collapses by another failure badociating the herbicide with cancer

The the reductions in Germany represent about 14% of the total workforce of the company, which has 32,100 workers. About 3,000 jobs represent positions in areas such as information technology and administrative functions, said people familiar with the situation, who asked that their identities not be revealed because the numbers do not match. have not yet been made public.

The The total reduction of 10% includes approximately 4,100 positions in Bayer's agricultural unit around the world, approximately 1,100 in the consumer health division, approximately 900 in research and development, and another 350 related to the closing of a business. German factory produces a treatment for hemophilia.

Although Baumann said the reorganization had nothing to do with glyphosate demands, legal issues reinforce Bayer's need to prove that the deal is operational success. More than 11,200 people sued for allegation of chemical agent relationship with cancer. Until now, there have been two jury trials. Bayer lost both. The company denies any link to cancer and has agreed to appeal in both cases.